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Abstract:	  Background: During last years, DNA vaccine immunogenicity has been optimized by the 
employment of co-stimulatory molecules and molecular adjuvants. It has been reported that plasmid 
(pATRex), encompassing the DNA sequence for the von Willebrand A (vWA/A) domain of the An-
thrax Toxin Receptor-1 (ANTXR-1, alias TEM8, Tumor Endothelial Marker 8), acts as strong im-
mune adjuvant by inducing formation of insoluble intracellular aggregates. Markedly, we faced with 
upsetting findings regarding the safety of pATRex as adjuvant since the aggregosome formation 
prompted to osteopenia in mice. 	  
Objective: The present study provides additional evidences about the proteinaceous adjuvants action 
within bone marrow and questioned regarding the self-aggregation protein adjuvants immunotoxicity 
on marrow niches.	  
Methods & Results: Using histological, biochemical and proteomic assays we shed light on pATRex 
effects within bone marrow niche and specifically we evidenced an aplastic-like bone marrow with 
disrupted cytokine/chemokine production.	  
Conclusion: The above findings provide compelling support to the thesis that adjuvants based on 
plasmids encoding protein aggregation domains disrupt the physiological features of the bone marrow 
elements. 
Keywords: Bone marrow, Bone marrow niche, Osteopenia, DNA vaccines, Adjuvants, Protein aggregates.	  
1. INTRODUCTION	  
The central dogma behind DNA vaccines is to induce 
immune responses against recombinant antigens encoded by 
genetically engineered DNA plasmids expressed in vivo. 
After immunization, host cellular apparatus enables the ex-
pression of plasmid-encoded genes, and consequently the 
activation of both major histocompatibility complex class I 
and class II molecules [1]. DNA vaccines provide high toler-
ability and safety and can be rapidly produced, but are typi-
cally hampered by reduced immunogenicity. An approach 
that has been effective in increasing DNA vaccine immuno-
genicity is the use of “vaccine cocktails” containing the 
DNA vaccine as well as plasmids encoding immunomodula-
tory proteins. Molecular adjuvant plasmids expressing cyto-
kines,	  chemokines, or co-stimulatory molecules may be co-
administered with the antigenic DNA vaccine plasmid [2]. 
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Previously, we have demonstrated that plasmids encoding 
aggregation-promoting domains act as genetic adjuvants. 
These plasmids induce formation of insoluble intracellular 
aggregates (aggregosomes) that trigger caspase activation 
and apoptotic cell death leading to innate immune system 
activation. Of importance, we reported that a plasmid vector 
(pATRex) encompassing the DNA sequence for the von 
Willebrand I/A domain (VWA) of tumor endothelial marker-
8 (TEM8, alias Anthrax Toxin Receptor-1) when given in 
combination with DNA encoding tumor associated antigens 
(TAA) enhanced immune protection against various tumors 
(e.g. breast cancer, melanoma) and infectious disease (e.g. 
malaria) [3, 4]. Moreover, we addressed the question of 
whether there is any considerable immunotoxicity associated 
with the use of self-aggregating proteins as genetic adju-
vants. Remarkably, we uncovered a “hidden” reactogenicity 
of pATRex-derived aggregates, which reflected in os-
teopenia. Indeed, we focused on long bones examination due 
to their peculiar feature as read-out system for immunotoxic-
ity [5-8]. Namely, it has been observed a cortical and trabe-
cular bone loss with concomitant disruption of bone mineral 
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content and a decrease of bone forming markers in pATRex 
treated mice. The osteo-disruptive scenario observed after 
pATRex administration was also accompanied with bone 
remodeling failure and fatty infiltration within bone marrow 
reservoir [9]. The above observations clearly depict the un-
comfortable hypothesis to employ these proteinaceous 
“sticky” adjuvants into practical vaccination protocols be-
cause of their deleterious skeletal effects. 	  
Of importance, the study of the proteotoxic aggregates 
that chronically activate the innate immune system in amy-
loid and aggregosome associated disorders remains complex 
and under concurrent investigation.	  
In this view, we extended our analyses on pATRex ef-
fects on bone marrow landscape, a nest for function, homing, 
migration and selective retainment of innate and adaptive 
progenitor and mature immune cells [8, 10]. The bone mar-
row dynamic operational microareas (referred as niches) are 
depicted by interdependence and interconnectedness and 
establish numerous physical, autocrine or paracrine type of 
interactions involving cytokines/chemokines, growth factors 
and other signaling molecules, which guaranty the steady 
state functions of this composite machinery [8]. The bone 
marrow multi niche concept (some authors have coined the 
niches as endosteal and vascular in relation of their topogra-
phy into bones) is thus characterized by an elegant poise 
between the hematopoietic and stromal components. Some 
reports have already described the ability of intramuscular 
injected plasmid to reach the bone marrow and to be assimi-
lated by resident immune-components such as neutrophils 
and monocytes [11, 12]. Hence, in this study, we assessed 
whether plasmid encoding ATRex administration in mice 
could perturb bone marrow homeostasis and modify niche 
functional features. These results could exert a peculiar sig-
nificance considering also the direct link between aggre-
gosome (amyloid peptides) formation and neurodegenerative 
diseases.	  
2. MATERIALS & METHODS	  
2.1. DNA Plasmids	  
For DNA immunizations, large scale preparation of the 
plasmids was routinely performed by alkaline lysis using 
Qiagen Plasmid Maxi kits (Qiagen). To assure endotoxin 
free products, DNA plasmids were purified using either 
Endo Free Plasmid Kit (Qiagen) or Gen Elute HPSelect 
Plasmid Giga Prep columns (Sigma # NA0800).	  
2.2. Animals Trials	  
All the experimental protocols implicated in this study 
were achieved from our previously work [9] and thus, for 
animals, treatments and tissue collection the reader must 
refer to above cited article. This manuscript represents a se-
quential part of the initial one.	  
Briefly, female and male FVB and Balb/c mice (Harlan 
Italy SrL, Correzzana Milano, Italy) were used. Mice were 
kept in laminar-flow cage in a standardized environmental 
condition. Mice (6-8 weeks old) were randomized in four 
groups (6 mice for each group). The groups were intramuscu- 
larly (i.m.) injected into the hind limb on time per week for 3 
weeks as follows: one group of mice (n = 6) received 100 µg 
of ATRex DNA (experimental) in saline; the second group 
of mice (n = 6) received 100 µg of ANTXR-1 DNA (control, 
coding for the parental ANTXR-1, alias TEM8) in saline; the 
third group of mice (n = 6) received 100 µg pcDNA3.1 (scaf-
fold plasmid) in saline; the fourth group of mice (n = 6) re-
ceived only saline. 	  
Mice from all groups were sacrificed at 90th days after 
the first injection by CO2 narcosis according to the recom-
mendation of the Italian Ethical Committee and under the 
supervision of authorized investigators. To evaluate the sys-
temic effects of the injection sites, plasmids were injected 
either into the left or right quadriceps, and counter-lateral 
bone collected.	  
2.3. Histological Bone Analysis and Immunohistochemi-
cal Staining	  
Femurs, dissected from adhering tissues, were fixed in 
4% PFA and decalcified as previously described [13]. Sam-
ples were embedded with Tissue-Tek OCT compound. Then, 
12 µm thick sections of femurs were obtained by a rotatory -
30°C air-dried microtome cryostat (Ames Cryostat Miles). 
Sections were stained with toluidine blue or with hematox-
ylin and eosin (H&E) stains.	  
Other sections, after rinsing with PBS and incubation 
with 0,3% H2O2 were incubated with blocking buffer (0.3% 
Triton X-100 and 1% BSA in PBS) containing 10% normal 
serum for 30-60 min at RT in a humidified chamber. Then, 
sections were incubated 1 h a RT with the following primary 
antibodies diluted 1:80 in blocking buffer: rabbit anti-Osterix 
(Santa Cruz Biotechnology, DBA, Milano, Italy); rabbit anti-
CXCL12 (Abcam; Prodotti Gianni, Milano, Italy); mouse 
anti-nestin (Abcam; Prodotti Gianni, Milano, Italy). After 
washing in PBS, sections were incubated for 30 min at RT 
with a biotinylated goat anti-mouse IgG (Vector Laborato-
ries, DBA Milano, Italy) or with a biotinylated goat anti-
rabbit IgG (Bethyl Laboratories, Aurogene s.r.l., Roma, It-
aly) both diluted 1:200 in blocking buffer. Control experi-
ments were performed by omitting the primary antibody. 
Slides were imaged using a Leica DM 2500 microscope.	  
2.4. Quantitative Analysis of Immunohistochemistry	  
High-resolution, 36-megapixel, digital micrographs were 
taken of defined bone marrow using a Leica DM 2500 opti-
cal microscope. Freely available software ImageJ software 
[version 1.34j, National Institutes of Health (NIH)] quanti-
fied pixel intensity. 	  
2.5. Total Bone Marrow Cell (BMCs) Derivation and 
Cultures	  
Long bones (femurs, tibiae and humeri) from the mice 
groups were dissected and the marrow cavity was flushed as 
previously described [13]. Total bone marrow cells (BMCs) 
were cultured for 3 days in DMEM containing 10% heat-
inactivated-fetal calf serum (HIFCS), penicillin and strepto-
mycin (Invitrogen, Milano, Italy). Then, the culture medium 
was collected to study the BMCs release of cytokines and 
chemokines while cells were used to perform western blot-
ting analysis.	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2.6. Western Blotting	  
Proteins from BMCs were extracted in cell lysis buffer 
(Cell Signaling, EuroClone, Milano, Italy) after 3 days of 
culture, and the concentration was determined by the BCA 
protein assay reagent (Pierce, EuroClone). Western blotting 
was performed as previously described [14]. Membranes 
were immunoblotted in blocking buffer with rabbit anti-
CXCL12 or with rabbit anti-CXCR4 (Abcam, Prodotti 
Gianni, Milano, Italy) both diluted 1:600. After washing 
with PBS-T, blots were incubated with horseradish peroxi-
dase (HRP)-conjugated donkey anti-rabbit IgG IgG (Cell 
Signaling, EuroClone) diluted 1:100,000.	  
Immunoreactive bands were visualized using LiteAblot 
Turbo luminol reagents (EuroClone) and Hyperfilm- ECL 
film (EuroClone) according to the manufacturer’s instruc-
tions. To normalize the bands, filters were stripped and re-
probed with a monoclonal anti-α-tubulin (Sigma-Aldrich). 
Band density was quantified densitometrically.	  
2.7. Cytokines and Chemokines Assay	  
The cytokine/chemokine profiles in supernatants of 3-day 
cultured BMCs population were assessed by using Mouse 
Cytokine Array Panel A kit (R&D Systems, Milano, Italy) 
accordingly to the manufacturer’s instructions. Briefly, after 
3 days in culture BMCs supernatant (600 µl) from each ex-
perimental group was incubated overnight on nitrocellulose 
membranes spotted with specific antibodies. Chemilumines-
cence detection produced signals (blots) directly proportional 
to the amount of cytokine bound. Immunoreactive dots were 
visualized using LiteAblot Turbo luminol reagents (Euro-
Clone, Milano, Italy) and Hyperfilm-ECL film (EuroClone, 
Milano, Italy) and quantitated densitometrically using Image 
J software.	  
2.8. Statistical Analysis	  
GraphPad Prism 5.0 for Macintosh was used for drawing 
graphs and for statistical analysis (GraphPad Software, San 
Diego, CA, USA). All experiments were repeated at least 
three times. t- student test was used to test for significant 
differences (*p< 0.05) between two groups.	  
3. RESULTS & DISCUSSION	  
Specialized cellular compartments within the bone cavi-
ties establish dynamic operational microareas designated as 
niches. The niche milieu encompasses a panorama of stem 
and progenitor elements as well as mature cells characterized 
by a complex symbiotic type of relationship [8, 15].	  
In this study, we showed the bone marrow niche modifi-
cation of mice administered with plasmids encoding protein 
aggregation domains. Bearing in mind that these genetic 
adjuvants form intracellular protein aggregates and thus en-
hance the immunogenic host response, we faced with ques-
tionable results regarding the safety of the “aggregosome 
adjuvant”. 	  
Likewise, with biochemical, western blotting and histo- 
logical methods, we shed light on pATRex effects on bone 
marrow reservoir due to the peculiarity of this multi-niche 
environment as the principal hematopoietic and osteogenic 
source [8].	  
As a first approach, histological sections of mice femurs 
were stained with toluidine blue and hematoxilin/eosin stain-
ing for the evaluation of the bone marrow structural details 
and bone marrow cellularity. Of note, pATRex-treated fe-
murs evidenced an ectopic invasion of adipocytes within 
bone marrow, mainly located in the sub-metaphyseal region 
and gradually decreased towards the femur diaphyseal area 
(Fig. 1A, B). Previous data demonstrated that adipocyte infil-
tration within bone marrow compartment could modify the 
clonal bias of certain HSC subpopulation, could disrupt the 
MSC and HSC commitment due to impaired cell-cell inter-
action and could alter production of key role niche elements 
such as cytokines and chemokines [16]. In this view, bio-
chemical studies were performed to evaluate the cytoki-
nes/chemokines release in the culture medium of BMCs re-
trieved from pATRex-treated and ANTXR1-administrated 
group of mice. Specifically, an increase of the interleukin 
(IL)-1a, IL-1b, IL-6, IL-7, IL-17, IL-27, was observed in 
BMCs from pATRex-treated group (Fig. 2A). Indeed, such 
cytokines are well known participants on osteoclast differen-
tiation and function, myeloid differentiation, HSC prolifera-
tion and in full-blown inflammatory plateau [8, 17, 18]. On 
the contrary, cytokines devised as anti-inflammatory such as 
IL-1ra, IL-5 and IL-10 [8, 17, 19] were found slightly re-
duced in BMCs from pATRex-injected mice (Fig. 2B). Also, 
given that cytokines exert a watchdog role in physiological 
conditions within bone marrow and control stromal compo-
nents and HSCs homing and egression, we showed that pA-
TRex-induced protein aggregates, provoke perturbations in 
the fine-tuned intramural cytokine trafficking. Thus, conven-
tional wisdom would suggest that pATRex administration 
scattered pro-inflammatory signaling cascades, disrupting 
the HSC homeostatic niche framework. 	  
Besides, niche ontogeny is characterized by interdepen-
dency of the various niche inhabitants, and explicitly (i) HSC 
functional attitudes are MSC/osteoblast-dependent [20], (ii) 
HSC and MSC pool play reciprocal regulation [8, 21, 22]. In 
this circumstantial, we questioned whereas aggregosomes 
could direct influence pre-osteoblast/MSCs population. Par-
ticularly, Nestin+ cells have been identified as MSC sub-
population within bone marrow responsible for HSC regula-
tion [23]. Moreover, Osterix+ (Osx+) osteolineage cells regu-
late the maturation of early B lymphoid precursors creating 
microniches for B cell development [24]. In addition, osteo-
pontin (OPN), matrix glycoprotein expressed by the os-
teoblasts, supports the migration and the adhesion of HSC 
toward to the osteoblastic niche and negatively regulates 
HSC proliferation, contributing to the maintenance of a qui-
escent state [25, 26]. In line, using immunohistochemical 
techniques we observed that MSC and osteoblast pool was 
reduced. Particularly, the decrease of Nestin+ and Osx+ 
pool, found in pATRex group compared with the control 
group, predicted variations of the endosteal niche cellular 
inhabitants (Fig. 3A, B). In addition, the reduction of OPN in 
pATRex-treated mice (Fig. 3C) could be ascribed to the di-
rect consequence of the reduction of the bone progeni-
tor/mature forming components. 
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Fig. (1). Representative sections H&E (A) and toluidine bleu (B) stained of femour sub-metaphyseal area after ANTXR1 or pATRex admini-
stration. Note the fat cells infiltration near the endosteal niche (red dashed line). Magnification 40x. N= 6 per group. 	  
	  
Fig. (2). Pro-inflammatory (A) and anti-inflammatory (B) cytokines and chemokines production from BMC cultures obtained by ANTXR1 
and pATRex treated mice was analyzed using Mouse Cytokine Array Panel A kit (R&D Systems, Milano, Italy) accordingly to the manufac-
turer’s instructions as specified in the M&M section. Immunoreactive spots were quantitated densitometrically using Image J software. 
(p<0.05) N= 6 per group.	  
The concurrent decrease in osteolineage cells with paral-
lel increase of fat cells in pATRex-treated mice group 
might predict a deregulation of MSC fate toward adipo-
genesis than osteogenesis. Nonetheless, previous our re-
sults sustained the above posture. Namely, in BMSCs of 
pATRex treated mice, we found a decrease of Runx2 and 
Osx, both widely recognized as the main transcriptional 
factors of osteoblast differentiation [9].  
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Fig. (4). Representative Western blotting of CXCL12 and its recep-
tor CXCR4 of total bone marrow population from femours of 
ANTXR1 and pATRex-treated mice. (p<0.05). N= 6 per group. 
Osteoblasts and MSCs express the soluble stromal-cell-
derived factor 1 (also termed as CXCL12), that binds to its 
specific receptor C-X-C chemokine receptor type 4 
(CXCR4) and prevents HSC mobilization supporting HSC 
maintenance [27, 28]. Interestingly, our findings revealed a 
reduced expression and a diminished perivascular distribu-
tion of CXCL12 in pATRex-treated mice in respect with 
control group (Fig. 3D). As further evidence, western blot-
ting analysis showed a reduce expression of CXCL12 and its 
receptor CXCR4 (Fig. 4). Since CXCL12/CXCR4 signaling 
regulates osteoclast recruitment, bone resorption, hema-
topoietic chemotaxis, fusion and cell survival [29, 30], we 
speculated that peculiar vascular niche metabolic feature, 
attributed to CXCL12/CXCR4 signaling, has been modified 
in the bone marrow of pATRex-treated mice. This instance is 
toughly buttressed by the observation of bone marrow 
hypocellularity in pATRex treated mice. Surprisingly we 
observed morphological modifications, which reflects in 
architectural niche changes. The vascular sinuses (Fig. 5A, 
C, E) were interspersed among adipocytes (Fig. 5A, C) and 
the endosteal niche cellularity were decreased with disrupted 
bone lining cell micro-architecture (Fig. 5B, D, F). The fact 
that there was no apparent change in appearance or distribu-
tion of the remaining hematopoietic tissue, predicting a de-
creased number of all hematopoietic cell lines in the bone
	  
Fig. (3). Immunohistochemistry and quantification of Nestin (A), Osx (B), OPN (C) and Cxcl12 (D) expression in pATRex-treated and 
ANTXR1-treated mice. Note the disrupted distribution of Nestin (A) and Cxcl12 (D) immunostaining in pATRex-treated cells; on the con-
trary ANTXR1-treated samples exhibit a localization pattern, primarily around the perivascular mesenchymal and endothelial cells lining the 
sinusoid throughout the bone marrow (arrows). TB: trabecular bone; S: sinusoid. Magnification 40x. N= 6 per group. 
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Fig. (5). Histological sections illustrate the bone marrow cellularity after ANTXR1 treatment with HSCs residing in close contact with vascu-
lar and perivascular cells but also megakaryocytes and other stromal cells (Aa, Ca); note also the distribution of the endosteal lining bone 
cells and the HSCs in close proximity (arrows) (Ba, Da). pATRex-treated group revealed a decrease in bone marrow hematopoietic cellular 
density at the perivascular (Ab, Cb) or endosteal (Bb, Db) compartments, probably due to adipocytes infiltration. Notably, after pATRex ad-
ministration the hematopoietic and stromal cells were found scattered among the fat cells and the sinus micro-architecture toughly disturbed 
by the adipocyte pool (E, F). The distinct, brown-colored, closely packed granules observed referred as hemosiderin granules particularly 
evident in pATRex-treated group. Hs: hemosiderin; S: sinusoid; A: adipocyte. Magnification A, C 40x; B, D, 60x. Reconstruction E, F. N= 6 
per group. 
marrow. In this scenario, H&E sections revealed an aplastic 
marrow, which appears devoid of hematopoietic cells, con-
sisting primarily of vascular sinuses and adipose tissue. The 
aplastic-like marrow was primarily observed at the sub-
metaphyseal level with a progressive reduction moving to-
wards the diaphysis of the mice femour. Considering that 
approximately 70 to 80% of the marrow being hematopoietic 
tissue in mice [31] and that changes in bone marrow cellula- 
rity can be an indicator of systemic toxicity affecting multi-
ple cell lineages [32], here we underscored the unseen reac-
togenicity of the aggregosome-induced adjuvants transduced 
in a pancytopenia-like condition.	  
CONCLUSION	  
In this report, we extended our knowledge concerning the 
safety of genetic adjuvants, which promote intracellular pro-
tein aggregates and sequentially induce frustrated autophagy 
and enhanced vaccine immunogenicity. Fully consistent with 
our previous observation in bone tissue, here we uncovered 
that protein aggregate formation, also seen in aggregosome 
disorders within a neurodegenerative proteinopathy scenario, 
disrupt bone marrow homeostatic features and drives to en-
feebled physical, autocrine and/or paracrine progeni-
tor/mature cell communication.	  
Considering that preceding studies evidenced that pA-
TRex DNA administration did not trigger histopathological 
changes in a wide array of soft tissues [3], we undoubtedly 
sustain that bones [9] and bone marrow remain the preferen-
tial target tissues of these injectable adjuvants in mice. This 
hypothesis is also consistent with other findings underlining 
that amyloid β peptides from Alzheimer patients have been 
found stored in osteoporotic bone tissue with concomitant 
increase of osteoclastic activity [33].	  
Collectively, our data point on the fact that, albeit the op-
tions for gene-based immunomodulatory proteins are consis-
tently developed, the real challenge resides in finding the 
optimal choice for each adjuvant that will lead to protective 
outcomes in clinical trials. 
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